Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,723 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-07 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 FIRST QUARTERLY REPORT
Regulatory Filings
2026-04-27 English
PROPOSED ADOPTION OF THE 2026 A SHARE EMPLOYEE STOCK OWNERSHIP SCHEME
Share Issue/Capital Change Classification · 80% confidence The document is a formal Hong Kong Exchange announcement by the Board of Shanghai Junshi Biosciences regarding the proposed adoption of a 2026 A‐Share Employee Stock Ownership Scheme. It is not a full annual or interim report, not a transcript, not a dividend or voting result, nor a management or earnings release. The content outlines terms for allocating shares (repurchased A‐shares) to employees, which falls under share capital arrangements. The closest category is Share Issue/Capital Change (SHA), covering announcements of new share schemes and capital structure changes under Chapter 17 of the Listing Rules.
2026-04-27 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE NINETEENTH MEETING OF THE FOURTH SESSION OF THE BOARD OF DIRECTORS
Regulatory Filings Classification · 85% confidence The document is an “Overseas Regulatory Announcement” detailing the resolutions passed at a Board of Directors meeting (approval of the first quarterly report and employee stock ownership plan, and related board authorisations). It is not the quarterly report itself (just a board approval), not a change in board or management composition, and not a proxy or earnings release. Therefore it falls under the general regulatory announcement/fallback category: RNS.
2026-04-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and simply notifies that an announcement has been published in another section. It does not include substantive financial or corporate details itself but serves only to inform readers that a report or announcement exists elsewhere. This matches the criteria for a Report Publication Announcement (RPA).
2026-04-27 English
2025 Annual Report
Regulatory Filings
2026-04-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.